Key result
Landiolol safely achieves rapid heart rate control in ACS and CTCA with minimal hypotension.
Why the study?
Literature focusing specifically on landiolol in coronary artery disease remains limited despite evolving beta-blocker strategies in acute myocardial infarction and the need for heart rate control during CTCA.
Landiolol represents a promising and safe ultra-short-acting beta-blocker for optimizing heart rate control in CAD management and cardiac imaging.
Answers are grounded in this paper and cite their sources.
May support landiolol for rapid heart rate control in ACS and CTCA; leaves open confirmation in larger prospective trials.
Coronary artery disease (CAD) constitutes a major contributor to morbidity, mortality and healthcare burden worldwide. Recent innovations in imaging modalities, pharmaceuticals and interventional techniques have revolutionized diagnostic and treatment options, necessitating the reevaluation of established drug protocols or the consideration of newer alternatives. The utilization of beta blockers (BBs) in the setting of acute myocardial infarction (AMI), shifting from the pre-reperfusion to the thrombolytic and finally the primary percutaneous coronary intervention (pPCI) era, has become increasingly more selective and contentious. Nonetheless, the extent of myocardial necrosis remains a key predictor of outcomes in this patient population, with large trials establishing the beneficial use of beta blockers. Computed tomography coronary angiography (CTCA) has emerged as a highly effective diagnostic tool for delineating the coronary anatomy and atheromatous plaque characteristics, with the added capability of MESH-3D model generation. Induction and preservation of a low heart rate (HR), regardless of the underlying sequence, is of critical importance for high-quality results. Landiolol is an intravenous beta blocker with an ultra-short duration of action (t1/2 = 4 min) and remarkable β1-receptor specificity (β1/β2 = 255) and pharmacokinetics that support its potential for systematic integration into clinical practice. It has been increasingly recognized for its importance in both acute (primarily studied in STEMI and, to a lesser extent, NSTEMI pPCI) and chronic (mainly studied in elective PCI) CAD settings. Given the limited literature focusing specifically on landiolol, the aim of this narrative review is to examine its pharmacological properties and evaluate its current and future role in enhancing both diagnostic imaging quality and therapeutic outcomes in patients with CAD.
No takes yet. Share an insight, caveat, or question.
Nasoufidou et al. (2025) conducted a review in Coronary Artery Disease, Acute Coronary Syndromes, and patients undergoing Computed Tomography Coronary Angiography. Landiolol vs. Placebo or conventional beta-blockers was evaluated. Landiolol safely and effectively achieves rapid heart rate control in acute coronary syndromes and improves diagnostic image quality during computed tomography coronary angiography with minimal hypotensive effects.
Synapse has enriched 10 related papers. Consider them for comparative context: